 Anand Patel
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 3 | 2020 | 83 | 2.360 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2021 | 18 | 0.900 |
Why?
| | Paraneoplastic Syndromes | 1 | 2021 | 17 | 0.900 |
Why?
| | Thrombocytopenia | 2 | 2021 | 171 | 0.880 |
Why?
| | Pyrrolidines | 1 | 2020 | 57 | 0.860 |
Why?
| | Aminopyridines | 1 | 2020 | 29 | 0.840 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 31 | 0.840 |
Why?
| | Triazines | 1 | 2020 | 48 | 0.820 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2020 | 43 | 0.820 |
Why?
| | Benzamides | 1 | 2020 | 217 | 0.820 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2021 | 84 | 0.820 |
Why?
| | Lymphoma, Follicular | 1 | 2020 | 68 | 0.810 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 249 | 0.770 |
Why?
| | Sulfonamides | 1 | 2020 | 328 | 0.730 |
Why?
| | Myelodysplastic Syndromes | 1 | 2021 | 315 | 0.720 |
Why?
| | Disease Management | 4 | 2020 | 339 | 0.710 |
Why?
| | Pyrimidines | 1 | 2020 | 399 | 0.690 |
Why?
| | Disease Susceptibility | 3 | 2020 | 183 | 0.610 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 2022 | 661 | 0.580 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2021 | 305 | 0.520 |
Why?
| | Antibodies, Bispecific | 3 | 2021 | 18 | 0.500 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2115 | 0.370 |
Why?
| | Humans | 23 | 2022 | 82932 | 0.340 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 811 | 0.310 |
Why?
| | Disease Progression | 2 | 2020 | 1468 | 0.310 |
Why?
| | Treatment Outcome | 5 | 2021 | 7874 | 0.300 |
Why?
| | Cytogenetics | 1 | 2021 | 26 | 0.240 |
Why?
| | Diagnosis, Differential | 2 | 2019 | 1604 | 0.240 |
Why?
| | Mutation | 4 | 2021 | 3848 | 0.230 |
Why?
| | Immunocompetence | 1 | 2021 | 26 | 0.230 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2021 | 109 | 0.230 |
Why?
| | Uridine | 1 | 2021 | 53 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2020 | 10 | 0.220 |
Why?
| | Janus Kinases | 1 | 2020 | 22 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 2 | 2020 | 2213 | 0.220 |
Why?
| | Translocation, Genetic | 1 | 2021 | 263 | 0.220 |
Why?
| | Middle Aged | 7 | 2021 | 25565 | 0.220 |
Why?
| | Azacitidine | 1 | 2021 | 122 | 0.220 |
Why?
| | Male | 8 | 2021 | 41802 | 0.210 |
Why?
| | Retreatment | 1 | 2020 | 106 | 0.210 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 104 | 0.210 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 36 | 0.210 |
Why?
| | Chromosome Aberrations | 1 | 2021 | 397 | 0.200 |
Why?
| | Feedback | 1 | 2020 | 113 | 0.200 |
Why?
| | Uncertainty | 1 | 2019 | 57 | 0.200 |
Why?
| | Education, Medical, Graduate | 2 | 2020 | 332 | 0.200 |
Why?
| | Drug Resistance | 1 | 2020 | 266 | 0.200 |
Why?
| | Patient Care | 1 | 2020 | 88 | 0.200 |
Why?
| | Neoplasm Grading | 1 | 2020 | 321 | 0.190 |
Why?
| | Exercise | 1 | 2022 | 279 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2308 | 0.190 |
Why?
| | Environment | 1 | 2020 | 219 | 0.190 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 578 | 0.180 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 273 | 0.180 |
Why?
| | Genomics | 2 | 2020 | 643 | 0.180 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2020 | 410 | 0.180 |
Why?
| | Patient Care Team | 1 | 2019 | 275 | 0.170 |
Why?
| | Recurrence | 1 | 2020 | 1193 | 0.170 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 312 | 0.170 |
Why?
| | Referral and Consultation | 1 | 2019 | 323 | 0.160 |
Why?
| | Academic Medical Centers | 1 | 2019 | 391 | 0.160 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1681 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 564 | 0.160 |
Why?
| | Internal Medicine | 1 | 2019 | 344 | 0.150 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 448 | 0.150 |
Why?
| | Age Factors | 1 | 2020 | 1913 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1199 | 0.150 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6571 | 0.140 |
Why?
| | Blood Pressure | 1 | 2021 | 1196 | 0.140 |
Why?
| | Internship and Residency | 2 | 2020 | 897 | 0.140 |
Why?
| | Neoplasm Staging | 1 | 2020 | 1920 | 0.140 |
Why?
| | Aged | 6 | 2021 | 18473 | 0.140 |
Why?
| | Young Adult | 3 | 2020 | 5954 | 0.130 |
Why?
| | Sweet Syndrome | 1 | 2013 | 6 | 0.130 |
Why?
| | Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2012 | 3 | 0.130 |
Why?
| | Adolescent | 3 | 2020 | 9105 | 0.130 |
Why?
| | Histone Deacetylase 2 | 1 | 2012 | 6 | 0.130 |
Why?
| | African Americans | 1 | 2021 | 1167 | 0.120 |
Why?
| | Prognosis | 1 | 2020 | 3694 | 0.120 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2012 | 143 | 0.110 |
Why?
| | Adult | 5 | 2022 | 25931 | 0.110 |
Why?
| | Histones | 1 | 2012 | 308 | 0.100 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 293 | 0.100 |
Why?
| | Female | 4 | 2020 | 44644 | 0.100 |
Why?
| | Signal Transduction | 1 | 2020 | 3296 | 0.100 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 546 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2021 | 7582 | 0.080 |
Why?
| | Fever | 2 | 2021 | 126 | 0.080 |
Why?
| | Clinical Competence | 2 | 2022 | 693 | 0.070 |
Why?
| | B-Lymphocytes | 2 | 2021 | 793 | 0.070 |
Why?
| | Transcription Factors | 1 | 2012 | 1512 | 0.070 |
Why?
| | Animals | 2 | 2020 | 26911 | 0.070 |
Why?
| | Nuclear Proteins | 2 | 2018 | 694 | 0.050 |
Why?
| | Fatigue | 1 | 2021 | 168 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2020 | 115 | 0.050 |
Why?
| | Minority Groups | 1 | 2021 | 115 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2022 | 162 | 0.050 |
Why?
| | Information Dissemination | 1 | 2020 | 99 | 0.050 |
Why?
| | Weight Loss | 1 | 2021 | 232 | 0.050 |
Why?
| | Burnout, Professional | 1 | 2020 | 74 | 0.050 |
Why?
| | Boron Compounds | 1 | 2018 | 21 | 0.050 |
Why?
| | Remission Induction | 1 | 2020 | 712 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 973 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2018 | 78 | 0.050 |
Why?
| | Glycine | 1 | 2018 | 98 | 0.050 |
Why?
| | Treatment Failure | 1 | 2018 | 305 | 0.040 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 274 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2018 | 244 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1585 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 463 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2018 | 586 | 0.040 |
Why?
| | Chicago | 1 | 2019 | 1444 | 0.040 |
Why?
| | Cohort Studies | 1 | 2021 | 2703 | 0.030 |
Why?
| | Phenotype | 1 | 2020 | 2284 | 0.030 |
Why?
| | Leukocytosis | 1 | 2013 | 15 | 0.030 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2012 | 10 | 0.030 |
Why?
| | Co-Repressor Proteins | 1 | 2012 | 18 | 0.030 |
Why?
| | Physicians | 1 | 2019 | 601 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1207 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2013 | 100 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 2420 | 0.030 |
Why?
| | Histone Deacetylases | 1 | 2012 | 61 | 0.030 |
Why?
| | Protein Subunits | 1 | 2012 | 118 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2012 | 94 | 0.030 |
Why?
| | Neutrophils | 1 | 2013 | 285 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2568 | 0.030 |
Why?
| | Risk Factors | 1 | 2021 | 5396 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 766 | 0.030 |
Why?
| | Chromatin | 1 | 2012 | 339 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2012 | 408 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 942 | 0.020 |
Why?
| | United States | 1 | 2020 | 6273 | 0.020 |
Why?
| | Protein Binding | 1 | 2012 | 1503 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1167 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1211 | 0.020 |
Why?
| | Mice | 1 | 2018 | 11106 | 0.020 |
Why?
|
|
Patel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|